Bone Mineral Density Clinical Trial
Official title:
Vibration Intervention For Bone Enhancement In Childhood Cancer Survivors
Treatment for childhood cancer interferes with normal bone maturation such that maximal peak bone mass may never be attained by some survivors of childhood cancer. In childhood cancer survivors, a randomized trial evaluating the effectiveness of vitamin D and calcium supplementation among ALL survivors is currently underway; however, few other interventions have been offered for this at risk population. Recent evidence demonstrates that low magnitude; high frequency mechanical stimulation can improve bone quantity and quality, perhaps providing an alternative or adjunct to pharmacologic intervention in populations where additional medications are either contraindicated or not acceptable to the individuals at risk. This application proposes a prospective double blind randomized clinical trial of low magnitude, high frequency mechanical (LMHF) stimulation for childhood cancer survivors whose bone mineral density is one or more standard deviations below the mean for their age and gender.
Status | Completed |
Enrollment | 81 |
Est. completion date | March 2013 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 7 Years to 17 Years |
Eligibility |
Inclusion Criteria: 1. Previously treated for childhood cancer at SJCRH 2. Greater than or equal to 5 years from childhood cancer diagnosis 3. Age and gender matched lumbar or whole body BMD z-score of <or equal -1.0 4. Not undergoing active treatment for cancer 5. = 7 and <18 years of age 6. Able to stand for 10 minutes (May hold on to a support while standing) 7. Able to tolerate Calcium and Vitamin D supplements Exclusion Criteria: 1. Receiving pharmacologic interventions other than Calcium and Vitamin D supplements for reduced Bone Mineral density (e.g. bisphosphonates) 2. Pregnant female 3. Individuals with metal implants that prevent BMD analysis by Dual X-ray Absorptiometry (DXA) or Quantitative Computed Tomography (QTC) 4. Inability or unwillingness of research participant or legal guardian/representative to give written informed consent/assent. 5. Spinal deformity requiring bracing 6. Chronic oral glucocorticoid therapy 7. Diagnosis of hereditary retinoblastoma (bilateral disease, familial, or positive test), Li-Fraumeni syndrome (positive testing for p53 mutation), Gorlin syndrome/Basil Cell Nevus syndrome, Bloom syndrome, Fanconi anemia, Ataxia telangiectasia or xeroderma pigmentosa |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Gabrielle's Angel Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Change in Total Bone Mineral Content (BMC) Per Height Compared Between Intervention and Placebo Groups | Since this is considered a "pilot study" we did not adjust for multiple comparisons. These % changes were treated as continuous variables and analyzed using two way ANOVAs adjusting for stratification. | Baseline and 12 months after start of intervention | No |
Primary | Percent Change in Lumbar Spine Bone Mineral Content (BMC) Compared Between Intervention and Placebo Groups | Since this is considered a "pilot study" we did not adjust for multiple comparisons. These % changes were treated as continuous variables and analyzed using two way ANOVAs adjusting for stratification. | Baseline and 12 months after start of intervention/ | No |
Primary | Percent Change in Total Bone Mineral Density (BMD) Compared Between Intervention and Placebo Groups | Since this is considered a "pilot study" we did not adjust for multiple comparisons. These % changes were treated as continuous variables and analyzed using two way ANOVAs adjusting for stratification. | Baseline and 12 months after the intervention begins | No |
Primary | Percent Change in Lumbar Spine Bone Mineral Density (BMD) Compared Between Intervention and Placebo Groups | Since this is considered a "pilot study" we did not adjust for multiple comparisons. These % changes were treated as continuous variables and analyzed using two way ANOVAs adjusting for stratification. | Baseline and 12 months after the intervention begins | No |
Primary | Percent Change in Lumbar Spine Volumetric Bone Mineral Density (BMD) Compared Between Intervention and Placebo Groups | Since this is considered a "pilot study" we did not adjust for multiple comparisons. These % changes were treated as continuous variables and analyzed using two way ANOVAs adjusting for stratification. | Baseline and 12 months after the intervention begins | No |
Primary | Percent Change in Tibial Cortical Bone Compared Between the Intervention and Placebo Groups | Since this is considered a "pilot study" we did not adjust for multiple comparisons. These % changes were treated as continuous variables and analyzed using two way ANOVAs adjusting for stratification. | Baseline and 12 months after the intervention begins | No |
Primary | Percent Change in Cortical Bone Per Length Compared Between the Intervention and Placebo Groups | Since this is considered a "pilot study" we did not adjust for multiple comparisons. These % changes were treated as continuous variables and analyzed using two way ANOVAs adjusting for stratification. | Baseline and 12 months after the intervention begins | No |
Secondary | Mean Change in Aminoterminal Propeptide of Type I Procollagen (PINP) Compared Between the Intervention and Placebo Groups | Biological markers of bone formation and cytokines collected at baseline and 12 months were evaluated to see if there was change over time. | Baseline and 12 months after the intervention begins | No |
Secondary | Mean Change in Osteocalcin (OC) Compared Between the Intervention and Placebo Groups | Biological markers of bone formation and cytokines collected at baseline and 12 months were evaluated to see if there was change over time. | Baseline and 12 months after the intervention begins | No |
Secondary | Mean Change in Alkaline Phosphatase (ALP)-Skeletal (Bone Specific) Compared Between the Intervention and Placebo Groups | Biological markers of bone formation and cytokines collected at baseline and 12 months were evaluated to see if there was change over time. | Baseline and 12 months after the intervention begins | No |
Secondary | Mean Change in Carboxyterminal Telopeptide of Type I Collagen (ITCP) Compared Between the Intervention and Placebo Groups | Biological markers of bone formation and cytokines collected at baseline and 12 months were evaluated to see if there was change over time. | Baseline and 12 months after the intervention begins | No |
Secondary | Mean Change in Collagen Cross Linked N-Telepeptide (NTx) Compared Between the Intervention and Placebo Groups | Biological markers of bone formation and cytokines collected at baseline and 12 months were evaluated to see if there was change over time. BCE = Bone Collagen Equivalent. | Baseline and 12 months after the intervention begins | No |
Secondary | Mean Change in Bone Turnover Ratio (RANKL/OPG) Compared Between the Intervention and Placebo Groups | Biological markers evaluated are: Osteoprotegerin (OPG)/receptor activator nuclear factor kB ligand (sRANKL) index. Between-group comparisons used two-sample t-tests. Biomarkers and cytokines collected at baseline and 12 months were evaluated to see if there was change over time. Variables were log transformed for analysis. |
Baseline and 12 months after the intervention begins | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02561182 -
Bone Health in Patients With Overgrowth
|
||
Completed |
NCT05736640 -
Osseointegrated Transdermal Femoral Amputation Prostheses
|
N/A | |
Terminated |
NCT01460147 -
Osteoporosis and MRI Study in Hemophilia
|
N/A | |
Active, not recruiting |
NCT01798030 -
Vitamin D Retrospective Study and Role With Disease
|
||
Recruiting |
NCT05091086 -
The Optimal Long Term Treatment Strategy of Anti-resorptive Medications---The Extension of Denosumab Sequential Therapy
|
Phase 4 | |
Completed |
NCT06274203 -
High Dose Vitamin D Supplementation in Children With Sickle Cell Disease
|
N/A | |
Recruiting |
NCT02355340 -
Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture
|
||
Completed |
NCT03316625 -
Reference Curve on Bone Mineral Density in Young Adult: French Multicenter Study
|
N/A | |
Not yet recruiting |
NCT02369289 -
Bone Mineral Density in Israeli Female Vegans and Omnivores
|
N/A | |
Completed |
NCT00924560 -
A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females
|
Phase 2 | |
Completed |
NCT03400982 -
Reference Curve on Bone Mineral Density in Men
|
N/A | |
Recruiting |
NCT04900506 -
Surgical Approach in Hemiarthroplasty. A Randomized Clinical Trial Comparing Posterior and Anterior Approach
|
N/A | |
Completed |
NCT02491008 -
Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction
|
Phase 4 | |
Recruiting |
NCT01310465 -
The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion
|
Phase 4 | |
Completed |
NCT00619047 -
The Role of Impact Activity in Peripubertal Bone Accrual
|
N/A | |
Completed |
NCT04962854 -
Changes of Bone Mineral Density in Total Hip Arthroplasty
|
||
Not yet recruiting |
NCT03437239 -
BFR After Bicep Tenodesis
|
N/A | |
Completed |
NCT03753100 -
Periprosthetic Bone Remodeling in Femoral Neck Fracture Patients; a 5-year Follow up Study
|
N/A | |
Withdrawn |
NCT04761666 -
Influence of Verticalization on Bone Mineral Density and Biological Parameters of Bone Remodeling in Children With Severe Cerebral Palsy
|
||
Enrolling by invitation |
NCT03835793 -
Health After eaRly Menopause Due to Oophorectomy
|